New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London suggests that a virtual reality test in which participants "go to the shops" could offer a ...

Cognition Therapeutics, Inc. (NASDAQ:CGTX) revealed positive results from the exploratory Phase 2 SHIMMER study demonstrating that CT1812 produced strong therapeutic responses across behavioral, ...

FORT COLLINS, CO - January 15, 2026 - - Institute of Clinical Excellence has highlighted cognitive functional therapy as an evidence-based clinical approach for managing persistent pain, drawing on ...

November 10, 2010 — A new study provides more evidence that functional magnetic resonance imaging (fMRI) can provide additional insight into the cognitive status of patients with disorders of ...

Please provide your email address to receive an email when new articles are posted on . Eli Lilly & Co.’s donanemab slowed cognitive and functional decline in people with early Alzheimer’s. The phase ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders including dementia with Lewy bodies (DLB), had the opportunity to raise ...

Please provide your email address to receive an email when new articles are posted on . A pill containing antihypertensives and a statin, with or without aspirin, was associated with reduced ...

A polypill that targets vascular risk factors may help slow functional decline in older adults, new research suggests. However, an analysis from the International Polycap Study (TIPS-3) showed that ...